81 results
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
27 Sep 24
Regulation FD Disclosure
7:00am
inhibitor; AKTi = serine/threonine protein kinase 1 A majority of all breast cancersare estrogen receptor positive (ER+) Current ER targeting agents
8-K
EX-99.1
OLMA
Olema Pharmaceuticals, Inc.
15 May 24
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
7:06am
treatment). The majority of patients (37 or 74%) were 2nd/3rd line+, with 37 (74%) patients having received prior endocrine therapy for metastatic breast … up to the RP2D of 120 mg was well tolerated with no dose-limiting toxicities, and the maximum tolerated dose (MTD) was not reached. The majority
8-K
OLMA
Olema Pharmaceuticals, Inc.
15 May 24
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
7:06am
dose (“RP2D”) of 120 mg once daily) plus ribociclib 600 mg once daily (three weeks followed by one week off treatment). The majority of patients (37 … was well tolerated with no dose-limiting toxicities, and the maximum tolerated dose (“MTD”) was not reached. The majority of treatment-emergent adverse
8-K
EX-99.1
x26 8yx1h1
8 Jan 24
Olema Oncology JP Morgan Conference January 2024
9:07am
424B5
ep4sr
5 Jan 24
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
5h4h0upntfgcu0jnjz
6 Dec 23
Regulation FD Disclosure
7:48am
8-K
0xw3w
5 Dec 23
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
5:15pm
8-K
EX-99.1
mzws2ifwdvap7f1f7
5 Dec 23
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
5:15pm
8-K
c8waz8svs4dtjy6 2dxq
23 Oct 23
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
7:45am
8-K
EX-99.1
elyyec8m
23 Oct 23
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
7:45am
8-K
EX-10.1
7a7 445sqrmbweeuvu
5 Sep 23
Olema Oncology Announces Combined Financing for Up to $180 Million
7:39am
8-K
EX-10.2
iid odlmu
5 Sep 23
Olema Oncology Announces Combined Financing for Up to $180 Million
7:39am
8-K
EX-99.1
nomu2icwf9rbp
11 May 23
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
9:24am